

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Manko Joseph M. Jr.</u> (Last) (First) (Middle) <u>1717 ARCH STREET</u> <u>37TH FLOOR</u> (Street) <u>PHILADELPHIA PA 19103</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>KORU Medical Systems, Inc. [KRMD]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>06/30/2025</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
--	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/30/2025		A		4,189	A	\$0 ⁽¹⁾	5,867,419	I	By Horton Capital Partners Fund, LP ⁽²⁾
Common Stock								517,200	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

1. Name and Address of Reporting Person * <u>Manko Joseph M. Jr.</u> (Last) (First) (Middle) <u>1717 ARCH STREET</u> <u>37TH FLOOR</u> (Street) <u>PHILADELPHIA PA 19103</u> (City) (State) (Zip)
1. Name and Address of Reporting Person * <u>Horton Capital Management, LLC</u> (Last) (First) (Middle) <u>1717 ARCH STREET</u> <u>37TH FLOOR</u> (Street) <u>PHILADELPHIA PA 19103</u> (City) (State) (Zip)
1. Name and Address of Reporting Person *

Horton Capital Partners, LLC

(Last)	(First)	(Middle)
1717 ARCH STREET		
37TH FLOOR		

(Street)		
PHILADELPHIA	PA	19103

(City)	(State)	(Zip)
--------	---------	-------

1. Name and Address of Reporting Person *

Horton Capital Partners Fund, L.P.

(Last)	(First)	(Middle)
1717 ARCH STREET		
37TH FLOOR		

(Street)		
PHILADELPHIA	PA	19103

(City)	(State)	(Zip)
--------	---------	-------

Explanation of Responses:

1. See Exhibit 99.1 to this Form 4 for explanation of note (1).
2. See Exhibit 99.1 to this Form 4 for explanation of note (2).

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

/s/ Joseph M. Manko, Jr. 07/02/2025

/s/ Joseph M. Manko, Jr.,
Managing Member of Horton 07/02/2025
Capital Management, LLC

/s/ Joseph M. Manko, Jr.,
Managing Member of Horton 07/02/2025
Capital Partners, LLC

/s/ Joseph M. Manko, Jr.,
Managing Member of Horton
Capital Partners, LLC, the General 07/02/2025
Partner of Horton Capital Partners
Fund, LP

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXHIBIT 99.1 TO FORM 4

Explanation of Responses:

- (1) On June 30, 2025, Horton Capital Partners Fund, LP, a Delaware limited partnership (“HCPF”), was granted 4,189 shares of Koru Medical Systems, Inc. (the “Issuer”) common stock (“Common Stock”) in consideration for Mr. Manko’s service as a Director of the Issuer for the quarter ended June 30, 2025.
- (2) This Form 4 is filed jointly by Horton Capital Management, LLC, a Delaware limited liability company (“HCM”), Horton Capital Partners, LLC, a Delaware limited liability company (“HCP”), HCPF, and Joseph M. Manko, Jr. Pursuant to investment advisory agreements, HCM maintains investment and voting power with respect to shares of Common Stock of the Issuer held by HCPF. However, despite the delegation of investment and voting power to HCM, HCP may be deemed to be the beneficial owner of such Common Stock because, in the event HCM’s investment advisory agreement with respect to such Common Stock is terminated, HCP has the right to assume HCM’s discretionary investment and voting authority with respect to such Common Stock. HCP is the general partner of HCPF. Mr. Manko is the managing member of both HCM and HCP. Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.
